Physician profile
Igor Medic
NPI 1154618593
$12,525.46
in general payments reported to CMS, 2019-2025
73 companies · $3,052 in 2025
The $3,052 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $107 · 2021: $264 · 2022: $1,705 · 2023: $3,466 · 2024: $3,342 · 2025: $3,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,429 · Long Term Medical Supply Or Device Loan: $299 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,428.61 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $132.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,461.85 | 2021-2025 | |
| Celgene Corporation | $752.98 | 2019-2025 | Reblozyl, Breyanzi, Pomalyst |
| Pfizer INC. | $656.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $583.09 | 2019-2025 | Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $570.04 | 2019-2025 | Abecma, Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $563.44 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $366.90 | 2019-2025 | |
| Janssen Biotech, INC. | $342.92 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $337.85 | 2019-2025 | Padcev, Xtandi, Xospata |
| Eisai INC. | $336.09 | 2022-2025 | |
| Abbvie INC. | $314.96 | 2020-2025 | |
| Glaxosmithkline, LLC. | $310.34 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $289.78 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Incyte Corporation | $286.27 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $270.05 | 2022-2023 | Imbruvica |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $268.06 | 2020-2023 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $261.92 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $261.86 | 2022-2025 | |
| Gilead Sciences, INC. | $248.59 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $232.32 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Array Biopharma INC | $220.01 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Karyopharm Therapeutics INC. | $207.17 | 2021-2025 | Xpovio |
| Blueprint Medicines Corporation | $199.41 | 2022-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $182.80 | 2022-2024 | Ultomiris |
| Amgen INC. | $166.91 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Beigene USA, INC. | $161.47 | 2021-2025 | Brukinsa |
| Lilly USA, LLC | $155.31 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $145.60 | 2022-2025 | Libtayo, Lynozyfic |
| Tersera Therapeutics LLC | $133.50 | 2023-2025 | Zoladex, Quzyttir, Xermelo |
| Deciphera Pharmaceuticals INC. | $117.49 | 2023-2025 | Qinlock, Tgct, Romvimza |
| Exelixis INC. | $117.37 | 2019-2024 | Cabometyx |
| Boston Scientific Corporation | $116.06 | 2019 | |
| Stemline Therapeutics INC. | $97.56 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $85.46 | 2019-2025 | |
| Adc Therapeutics America, INC. | $82.07 | 2023-2025 | |
| Springworks Therapeutics, INC. | $81.58 | 2024-2025 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $79.74 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Taiho Oncology, INC. | $76.41 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $68.87 | 2023-2024 | Clonoseq |
| Coherus Oncology, INC. | $68.69 | 2022-2023 | |
| Beone Medicines USA, INC. | $66.01 | 2025 | Tevimbra |
| Servier Pharmaceuticals LLC | $64.09 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $62.29 | 2023-2025 | Orgovyx |
| Geron Corporation | $61.04 | 2025 | Rytelo |
| Sobi, INC | $56.84 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $54.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.68 | 2022-2025 | |
| Verastem, INC. | $53.61 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $53.47 | 2024-2025 | |
| Tempus Ai, INC | $53.27 | 2024-2025 | Xt Cdx |
| Accord Healthcare, INC. | $50.68 | 2025 | |
| Syndax Pharmaceuticals, INC. | $49.45 | 2025 | |
| Mirati Therapeutics, INC. | $45.79 | 2023-2024 | Krazati |
| Recordati_rare_diseases_inc. | $45.68 | 2024-2025 | Sylvant |
| Pharmacosmos Therapeutics INC. | $42.41 | 2024-2025 | Monoferric |
| Novo Nordisk INC | $42.05 | 2023-2024 | Novoseven, Novoeight |
| Agios Pharmaceuticals, INC. | $41.17 | 2024-2025 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $39.41 | 2024-2025 | Fyarro, Pedmark |
| Emd Serono, INC. | $31.73 | 2019-2024 | |
| Kyowa Kirin, INC. | $29.56 | 2023 | Poteligeo |
| Octapharma USA, INC. | $24.89 | 2023 | Panzyga |
| Eusa Pharma (US) LLC | $24.30 | 2022 | |
| Kite Pharma, INC. | $23.85 | 2025 | Yescarta |
| Iovance Biotherapeutics, INC. | $22.38 | 2025 | Amtagvi |
| Morphosys, US INC. | $22.33 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.00 | 2023 | Empaveli |
| Tolmar, INC. | $18.53 | 2023 | |
| Menarini Silicon Biosystems, INC. | $18.50 | 2023 | Cellsearch |
| Immunocore Limited | $18.19 | 2024 | Kimmtrak |
| Janssen Pharmaceuticals, INC | $18.02 | 2019 | |
| Foundation Medicine, INC. | $16.97 | 2022 | |
| Heron Therapeutics, INC. | $13.63 | 2023 | Sustol |
| Emmaus Medical, INC. | $8.89 | 2023 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Medic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.